X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Report Indicates UK £62bn Behind In Global R&D Investment

Content Team by Content Team
3rd November 2022
in News, Research & Development
Report Indicates UK £62bn Behind In Global R&D Investment

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

According to a recent data study by the Institute for Public Policy Research, the UK’s share of worldwide research and development (R&D) spending has decreased by 5% since 2014.

Despite exceeding the government’s aim of 2.4% GDP for R&D expenditure, the UK ranks significantly below world leaders in R&D investment as a percentage of GDP, coming in at 11th place among OECD nations. In order to surpass Israel as the top R&D spender in 2022, the UK would have to make an additional £62 billion in investments.

If the UK’s worldwide share of R&D investment hadn’t fallen from 4.2% to 3.4% in 2014, it would have been £18 billion (26%) greater in 2019.

According to IPPR, public sector investment stimulates private sector investment. Investors would invest an incremental £1.36 billion over the course of a decade if the UK government invested an additional £1 billion in research and development. According to the report, investing in health research is a major way to increase R&D funding by crowdsourcing unique investments, aligning activity with more general social aims, and expressing a clear strategic direction.

The government should enhance public financing, the IPPR advises, to enable more NHS employees to participate in clinical research. According to the IPPR’s data, Germany has eight times as many government researchers as the UK.

IPPR suggests three paths the UK should take to strengthen its investment position.

A Little Ambitious

By 2027, achieve three percent of GDP, building on goals stated by the European Commission, the Confederation of British Industry, and opposition political parties.

By 2027, the government would need to provide an additional £1 billion to R&D. In the same year, private investment would also need to increase by £0.8 billion.

Greater Ambition

  • To match Sweden’s, the US’s, and Taiwan’s R&D spending levels by 2030, 3.5% of GDP must be reached.
  • By 2030, the government would need to invest an additional £8.5 billion in R&D.
  • In the same year, private investment would need to rise by £8.3 billion.

Genuine Global Leadership

  • By 2030, reach 5.4% of GDP, making the UK a global leader and nearly matching investments made by South Korea and Israel.
  • By 2030, public investment must increase by £43.1 billion.
  • In the same year, private investment would have to increase by £41.9 billion.

Shreya Nanda, an economist at the IPPR and the report’s author, claimed that the UK lags behind in both research and the development of innovative future technologies.

Nanda continued; R&D innovation is a crucial tool in combating this trend. To reinstate the UK’s top worldwide position, promote private sector investment, and ultimately produce economic development, they implore the government to increase R&D funding.

Previous Post

Wall Street Cautiously Optimistic After Gene Therapy Deals

Next Post

Cancer Clinical Trials Get A Brand New Platform In Melbourne

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post

Cancer Clinical Trials Get A Brand New Platform In Melbourne

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In